BMSN Today’s Subpenny Fall Kickoff Alert Has Triple Digit Gains Written All Over It
PennyStockLocks Newsletter
[1][jpeg]
Members,
A few days ago we told you that we have been scanning the market hard in search of the perfect alert to kick-off the fall season…
Well after days of research we have found what seems like the perfect pick to start the season off with…
We know how much you love those low priced subpennies, and their monster gain potential…
So its no surprise that we`re kicking off Fall with a red-hot subpenny alert!
Please turn your immediate attention to [2]BMSN ([3]Bio-Matrix Scientific Group Inc.)!
This red hot [4]Bio-Tech company is screaming breakout!
It`s not often we see a company operating in a $32 Billion industry trading under a penny…
So you shouldn`t be surprised when we tell you that BMSN may not be trading under a penny for much longer…
BMSN caught our attention yestedat when we watched it shoot up 25% on heavy volume…
The company closed well in the green, which is usually strong sign of bullish momentum to come!
The technicals look excellent right now, with the analyst`s at [5]barchart.com upgrading BMSN to a “[6]Strong Buy” for traders in the short, medium, and long term!
Now remember BMSN is a subpenny…
That means even the smallest move in price could equate to some serious gains…
Trading at just $0..0034, If BMSN were to hit $0.01, which it easily could, that would equate to nearly +200% in gains!
How many times have we watched our subpenny alerts explode for triple, sometimes quadruple digit gains in just one day
Right now BMSN has triple digit gains written all over it!
Yesterday we told you to expect news this morning, however we have just been informed that there will not be a press release today.
We will keep you up to date regarding any updates from BMSN so keep an eye out!
We`ve watched BMSN move up more than 1,400% from its 52-week low of 0.0002 since December of last year…..
Could today be the start of its next +1,000% run
We certainly don`t want you to miss out on this huge profit opportunity, that is why we are urging all members to immediately put BMSN on the top of their watch list, and be ready today at 9:30am EST!
Start your research now, and view BMSN`s Full Profile, Latest News, and Chart below:
[7][png]
Company: Bio-Matrix Scientific Group Inc.
Symbol: [8]BMSN
Alert PPS: $0.0034
Website: [9]www[10]..[11]regenbiopharma.com
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.
BMSN is pursuing relationships with hospitals, medical institutes, research firms and biotechnology companies to assist in stem cell research, cell culturing and Regenerative Medicine therapies.
BMSN’s facilities are available for processing, culturing and storage of specimens. Also, under certain situations, the Company has laboratories available to organizations conducting research.
BMSN`s subsidiary [12]Regen BioPharma, Inc. is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
The company released big news yesterday when they announced that they are currently developing research plans for their breast cancer immunotherapeutic product, dCellVax. This cell therapy is based on patent # 8,389,708 obtained from Dr. Wei-Ping Min of the University of Western Ontario as well as an international patent portfolio licensed from Benitech Biopharma Ltd.
This is huge news as it is a huge step toward cementing BMSN`s place in a [13]multi-billion dollar breast cancer treatment market!
Strong Stem Cell Market Outlook Could Mean Huge Revenues For BMSN!
A new report by [14]visiongain predicts that the overall world market for stem cell technologies in medicine will reach $7.3 billion for 2014. That market will be stimulated by new treatments and increasing use of related products in drug development. Those findings appear in Stem Cell Technologies: World Market Outlook 2012-2022, published in May 2012. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the stem cells market will expand rapidly from 2012 to 2022, achieving multi-billion-dollar revenues worldwide. More than 200 companies operate in that field. The next ten years will result in many new medical products and uses for stem cells. The period to 2022 will establish the foundations of a therapeutic revolution, the report concludes.
Haematopoietic stem cell transplantation is an established treatment for blood cancers. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Banking of umbilical cord blood (other stem cell-containing blood units) and culturing and processing of stem cells for laboratory work are the other established business areas in 2012. That commercial activity is only the start, the report argues, with stem cell technologies poised for important advances by 2020.
Dr James Evans, a pharmaceutical industry analyst in visiongain, explains: “Stem cell technologies have been hyped for a long time, but it’s only now that we’re going to see the first approved products, treatments based on mesenchymal stem cells or improvements to stem cell transplants. Stem cell-based innovations are likely in the treatment of vascular diseases, autoimmune diseases, diabetes, dry AMD and other serious disorders. Some of these breakthroughs will be a commercial reality by 2022.”
“The use of stem cells in laboratory assays for drug development is a strong opportunity for the biotechnology industry. Stem cells offer an improved way to model diseases in vitro, identify candidate drugs and perform toxicity testing and other assays. With drug development costs and failures such a concern for the pharmaceutical industry, that segment will be important to the overall stem cells market, representing around a third of its revenues by 2022, our study predicts.”
With the forecast for the Stem Cell Market looking so positive right now, BMSN could be well on its way to record revenue numbers!
If BMSN were to tap into this booming market we could see its PPS explode for record breaking profits!
We don`t anticipate BMSN to be trading under a penny for much longer…
We are urging all members to immediately put BMSN on the top of their watchlist, and to be ready today at 9:30am EST…
Remember The first step to becoming a successful penny stock trader is opening up a brokerage account if you haven`t done so already you can start by clicking [15]here.
***Always Trade Smart & Take Profits When You Can***
Sincerely,
The PennyStockLocks Team
P.S.
Share the wealth and forward this email to all your fellow traders who have yet to join the fastest growing network of serious traders on the web.
Related posts:
- Re- open this now “You’ll Thank Me”
- I ‘Nailed’ AAPH Again Hit 43 Cents
- MDFI My New Potential Quick Doubler
- For Those Who Requested More Details on AAST (News = Breakout)
- THWI competitor recently bought for over $100Mill